Summary: OncoHost will present at the ASCO Annual Meeting, highlighting the PROphet platform’s capability to predict clinical benefits from immune checkpoint inhibitor therapies across various cancers.


  1. The PROphet platform predicts treatment outcomes by analyzing proteomic profiles in pre-treatment blood plasma using advanced bioinformatics and machine learning.
  2. Initially developed for metastatic non-small cell lung cancer, PROphet’s predictive accuracy extends to melanoma and HPV-related cancers.
  3. The study, conducted with top medical institutions, underscores PROphet’s potential to enhance precision medicine and improve patient care through non-invasive testing.

OncoHost, a technology company providing precision medicine for improved patient outcomes, has announced that it will be delivering a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation will highlight the ability of the company’s PROphet platform to predict clinical benefit from immune checkpoint inhibitor (ICI)-based therapies across various cancer indications.

Further Reading: OncoHost Launches NSCLC Test in the U.S.

“ICIs represent a key treatment modality for a growing number of cancer types, but a gap exists in the availability of predictive tests that can accurately identify patients likely to benefit from these therapies. Our PROphet platform offers a solution,” says Ofer Sharon, MD, CEO at OncoHost. “This research highlights the adaptability of PROphet as we work to provide treatment guidance for multiple indications. I am proud of our team’s commitment to improving outcomes for cancer patients worldwide and the ongoing impact of our work in the oncology field.”

PROphet Platform: Novel and Robust Predictive Model

PROphet is a novel and robust predictive computational model that analyzes and identifies proteomic profiles in pre-treatment blood plasma by combining bioinformatics, system biology, proteomic pattern recognition and machine learning. PROphetNSCLC, the first indication for which the platform was developed, predicts clinical benefit from first-line PD-1/PD-L1 inhibitor-based therapies in patients with metastatic non-small cell lung cancer (mNSCLC), offering guidance in choosing between ICI monotherapy and ICI-chemotherapy combination.

Observational Study

For this observational study, pre-treatment plasma samples and clinical data were collected from patients with metastatic melanoma and HPV-related cancers undergoing treatment with PD-1/PD-L1 inhibitor-based therapies. HPV-related cancers included anogenital squamous cell carcinoma, cervical carcinoma, and head and neck squamous cell carcinoma. The presentation will showcase the findings which demonstrate the potential of the PROphetNSCLC test in predicting ICI response for indications beyond just NSCLC, underscoring the promise of PROphet in advancing precision medicine.

The study was conducted in collaboration with Sidney Kimmel Medical College at Thomas Jefferson University, Yale School of Medicine, and the Center for Immuno-Oncology, Center for Cancer Research of the National Cancer Institute.

“We are excited to present our latest findings at ASCO 2024,” says Itamar Sela, PhD, VP R&D at OncoHost and co-author of the study. “This study showcases the versatility of the PROphet platform in predicting benefit from immune-checkpoint inhibitors not only in NSCLC, but also in melanoma and HPV-related cancers. By leveraging the power of plasma-based proteomic analysis, PROphet offers a non-invasive and efficient method to guide treatment decisions and optimize patient care.”